WO2018203380A1 - Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes - Google Patents

Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes Download PDF

Info

Publication number
WO2018203380A1
WO2018203380A1 PCT/JP2017/017208 JP2017017208W WO2018203380A1 WO 2018203380 A1 WO2018203380 A1 WO 2018203380A1 JP 2017017208 W JP2017017208 W JP 2017017208W WO 2018203380 A1 WO2018203380 A1 WO 2018203380A1
Authority
WO
WIPO (PCT)
Prior art keywords
brown algae
weight
extract
algae extract
containing composition
Prior art date
Application number
PCT/JP2017/017208
Other languages
English (en)
Japanese (ja)
Inventor
増村光一郎
黒部耕司
Original Assignee
ラムズ・マークス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラムズ・マークス株式会社 filed Critical ラムズ・マークス株式会社
Priority to PCT/JP2017/017208 priority Critical patent/WO2018203380A1/fr
Publication of WO2018203380A1 publication Critical patent/WO2018203380A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention relates to a gel-like or liquid brown algae extract-containing composition containing a brown algae extract as a main component, and a brown algae extract-containing acupuncture prevention liquid.
  • ⁇ When a manic disease develops, it is generally embarrassed to go to the hospital because the diseased part is the anus, and it is common to deal with a commercially available medicine for manic diseases.
  • an external medicine for treating hemorrhoid disease for example, (a) 0.01 to 0.3% by mass of a refreshing agent, (b) 0.1 to 10% by mass of a gelling agent, and (c) 1 alcohol.
  • An agent for treating gel-like hemorrhoids containing 10 to 10% by mass, (d) 50 to 98% by mass of water, and (e) 3% by mass or less of a local anesthetic is disclosed (see Patent Document 1).
  • drugs for treating hemorrhoids include local anesthetic components such as lidocaine and dibucaine as described in Patent Document 1, and those that temporarily relieve pain, and refresher components such as menthol and camphor. There are those that have the effect of temporarily relieving itching of manic diseases.
  • a local anesthetic component or a refreshing agent component temporarily removes discomfort of a manic disease such as pain and itch, but cannot be an active ingredient for preventing or treating manic disease. Therefore, these drugs for treating hemorrhoids are only used as coping therapy drugs, and eventually, when the hemorrhoids worsen, there is a current situation in which surgical treatment is unavoidable by anal surgery or the like.
  • the present invention was devised in view of the above circumstances, and contains a brown alga extract-containing composition containing at least a brown algae extract as an active ingredient in order to prevent the induction of an epilepsy disease or to improve an epilepsy disease, and
  • the purpose is to provide a brown algae extract-containing acupuncture prevention liquid.
  • the brown algae extract-containing composition according to the present invention comprises a brown algae extract having a solid content of 0.10 to 10.00% by weight excluding moisture as a main component, and is medically acceptable as a remaining component. It is characterized by containing various components. Brown algae extract contains fucoidan, amino acid, diastase, alginic acid, and abundant minerals, and has been reported to have external effects such as moisturizing action and skin regenerating action. Therefore, the reason why the brown algae extract is a main component is that external effects such as a moisturizing action and a skin regenerating action are active ingredients for leprosy.
  • the remaining components include water, ethanol and the like and are medically acceptable components.
  • the brown algae extract is contained in a solid content of 0.10% by weight or more is that if it is less than 0.10%, a sufficient effect as an active ingredient of a manic disease cannot be obtained.
  • the brown algae extract is contained in an amount of 10.00% by weight or less as the solid content because if it exceeds 10.00% by weight, it is difficult to adjust the remaining components.
  • the solid content of the brown algae extract is preferably 0.10 to 3.00% by weight.
  • the reason why the solid content of the brown algae extract is set in the range of 0.10 to 3.00% by weight is that a particularly effective effect is obtained in this range.
  • the remaining component comprises at least 0.10 to 10.00% by weight of anti-inflammatory agent, 0.20 to 10.00% by weight of aloe extract, and 0.10 to 5.00% by weight of soluble protein component. It is preferable to contain.
  • the reason for containing the anti-inflammatory agent is to suppress inflammation of the manic disease.
  • the reason for containing 0.10% by weight or more of the anti-inflammatory agent is that if it is less than 0.10% by weight, it is difficult to obtain anti-inflammatory effects.
  • the reason why the anti-inflammatory agent is contained in an amount of 10.00% by weight or less is that when the amount exceeds 10.00% by weight, no difference is observed in the anti-inflammatory effect.
  • Aloe extract contains plant phenolic components such as aloin, polysaccharides components such as aloe mannan and gluconic acid, and other components such as aloetin, and also contains brown algal extract. It is because it can become an active ingredient.
  • Plant phenolic components have been reported to have external effects such as sedation and analgesia, bacterial growth inhibition, and enzyme activity suppression.
  • external effects such as skin beautification, wound healing, anti-inflammatory and sterilization have been reported for polysaccharide components.
  • aloetin has a strong antibacterial and antifungal effect for external use.
  • the reason why the aloe extract is contained by 0.20% by weight or more is that if it is less than 0.20% by weight, it is difficult to obtain an effect as an active ingredient.
  • the reason why Aloe extract is contained in an amount of 10.00% by weight or less is that no difference is observed in the efficacy as an active ingredient even if the amount exceeding 10.00% by weight is added.
  • the reason why the soluble protein component is contained is to promote the penetration into the skin.
  • the reason why the soluble protein component is contained in an amount of 0.10% by weight or more is that the permeability to the skin is inferior when the content is less than 0.10% by weight.
  • the reason why the soluble protein component is contained at 5.00% by weight or less is that no difference is observed in the permeability to the skin even if an amount exceeding 5.00% by weight is added.
  • the anti-inflammatory agent preferably contains at least one of glycyrrhizic acid 2K and allantoin.
  • the reason why the anti-inflammatory agent contains at least one kind of glycyrrhizic acid 2K and allantoin is that an anti-inflammatory effect can be obtained by including any of these components.
  • the aloe extract preferably contains at least one kind of aloe vera mesophyll, kidachi aloe mesophyll, cape aloe mesophyll, aloe vera leaf extract, kidachi aloe leaf extract, cape aloe leaf extract.
  • the aloe extract contains at least one of aloe vera mesophyll, kidachi aloe mesophyll, cape aloe mesophyll, aloe vera leaf extract, kidachi aloe leaf extract, cape aloe leaf extract. It is because the effect as is obtained. In order to increase the efficacy as an active ingredient, it is preferable to use a combination of a plurality of ingredients.
  • the soluble protein component is preferably hydrolyzed silk.
  • hydrolyzed silk By using hydrolyzed silk as the soluble protein component, good permeability to the skin can be ensured.
  • the brown algae extract-containing acupuncture prevention liquid according to the present invention is characterized in that the brown algae extract-containing composition according to any one of the above is used as a treatment prevention liquid for an epilepsy disease.
  • the brown algae extract-containing composition according to any of the above is used as a treatment / prevention solution for hemorrhoid disease.
  • the brown algae extract-containing composition according to the present invention, it contains at least a brown algae extract as an active ingredient, and can prevent the induction of epilepsy disease or promote improvement even if it has developed epilepsy disease. Demonstrate the excellent effect of being able to.
  • the brown algae extract according to the present embodiment is an extract extracted from brown algae such as mozuku, wakame and kelp. Seaweeds include green algae, brown algae, and red algae. In this embodiment, it is particularly preferable to use an extract of brown algae.
  • the extraction method of the brown algae extract is not limited, but it is preferable to remove harmful low-molecular substances such as arsenic. Therefore, although it is preferable to use a high molecular weight extract as the brown algae extract, it is not limited to this.
  • Brown algae extract contains fucoidan, amino acid, diastase, alginic acid, and abundant minerals, and has been reported to have external effects such as moisturizing action and skin regenerating action.
  • fucoidan a sulfated polysaccharide composed mainly of full-course sugar, has antitumor, anti-gastric ulcer, antiviral, anti-inflammatory, anticoagulant, immune enhancement, anti-type I allergy, antihyperlipidemia, etc. It has been reported to have various pharmacological actions (JP 2002-220402 A). Fucoidan is also used as a moisturizing ingredient in cosmetics and the like. Therefore, the brown algae extract-containing composition according to the present embodiment has the brown algae extract as a main component because external effects such as a moisturizing action and a skin regenerating action are effective ingredients for leprosy.
  • the brown algae extract-containing composition according to the present invention comprises a brown algae extract having a solid content of 0.10 to 10.00% by weight excluding moisture as a main component, and a medically acceptable component such as water or ethanol as a remaining component. contains.
  • the remaining components include at least 0.10 to 10.00% by weight of anti-inflammatory agent, 0.20 to 10.00% by weight of aloe extract (aloe leaf meat powder and / or aloe leaf extract), and 0 It is preferable to contain 10 to 5.00% by weight of a soluble protein component.
  • the solid content of the brown alga extract is preferably 0.10 to 3.00% by weight.
  • FIG. 1 shows the results of efficacy confirmation tests of Examples 1 to 5 and Comparative Examples 1 to 3.
  • the solid content of the brown algae extract as the main component is changed in the range of 0.5 to 15.0% by weight, and the remaining amount contains purified water and absolute ethanol.
  • the composition of the brown algae extract-containing composition of Example 1 is as follows.
  • the composition of the brown algae extract-containing composition of Example 2 is as follows. (Example 2) Solid content of brown algae extract: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 3 is as follows. (Example 3) Solid content of brown algae extract: 5.0% by weight Purified water and absolute ethanol: remaining
  • Example 4 Solid content of brown algae extract: 10.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 5 is as follows. (Example 5) Solid content of brown algae extract: 15.0% by weight Purified water and absolute ethanol: remaining
  • composition of the brown algae extract-containing composition of Comparative Example 1 is as follows. (Comparative Example 1) Solid content of brown algae extract: 0.05% by weight Purified water and absolute ethanol: remaining
  • composition of the brown algae extract-containing composition of Comparative Example 2 is as follows. (Comparative Example 2) Solid content of brown algae extract: 0.08% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 3 is as follows. (Comparative Example 3) Solid content of brown algae extract: 0.09 wt% Purified water and absolute ethanol: remaining
  • the brown algae extract-containing compositions of practical examples 1 to 5 by containing the solid content of the brown algae extract as the main component in the range of 0.10 to 15.00% by weight, the effect of improving the hemorrhoid disease was confirmed. Further, it was confirmed that the solid content of the brown algae extract is more preferably in the range of 0.10 to 3.00% by weight. However, the solid content of the brown algae extract is preferably set to 10.00 weight or less. Even if the solid content of the brown algae extract as the main component exceeds 10.00% by weight, there is no difference in the efficacy of the active ingredient, and if it exceeds 10.00% by weight, it will be difficult to adjust the remaining components described later. is there.
  • the solid content of the brown algae extract as the main component is appropriately set in the range of 0.05 wt% to 10.0 wt%, and the anti-inflammatory agent, aloe extract, and soluble protein component as the remaining components The content was examined.
  • FIG. 2 shows the results of the efficacy confirmation tests of Examples 6 to 11 and Comparative Examples 4 to 6.
  • the solid content of the brown algae extract as the main component is appropriately set in the range of 0.05 to 10.0% by weight, and the anti-inflammatory agent is in the range of 0.05 to 15.0% by weight.
  • the content is changed, and the remaining amount contains purified water and absolute ethanol.
  • the amount of aloe extract is set to 0% or 5.0% by weight
  • the amount of soluble protein is set to 0% or 3.0% by weight.
  • the composition of the brown algae extract-containing composition of Example 6 is as follows. (Example 6) Solid content of brown algae extract: 0.10% by weight Anti-inflammatory agent: 0.10% by weight Aloe extract: 5.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 7 is as follows. (Example 7) Solid content of brown algae extract: 3.0% by weight Anti-inflammatory agent: 0.50% by weight Aloe extract: 0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 8 is as follows. (Example 8) Solid content of brown algae extract: 5.0% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • Example 9 Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 10.0% by weight Aloe extract: 0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 10 is as follows. (Example 10) Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 15.0% by weight Aloe extract: 5.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 4 is as follows. (Comparative Example 4) Solid content of brown algae extract: 0.05% by weight Anti-inflammatory agent: 0.05% by weight Aloe extract: 0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 5 is as follows. (Comparative Example 5) Solid content of brown algae extract: 0.08% by weight Anti-inflammatory agent: 0.08% by weight Aloe extract: 5.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 6 is as follows. (Comparative Example 6) Solid content of brown algae extract: 0.09 wt% Anti-inflammatory agent: 0.09% by weight Aloe extract: 0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • an anti-inflammatory agent contained in the range of 0.10 to 15.0% by weight was effective in improving hemorrhoid disease.
  • the anti-inflammatory agent should be set in the range of 0.10 to 10.0% by weight. Is preferred.
  • an anti-inflammatory agent contains at least 1 sort (s) of glycyrrhizic acid 2K and allantoin, for example.
  • anti-inflammatory agents examples include glycyrrhizic acid 2K and allantoin, but are not limited to these exemplified agents, and are not intended to exclude other anti-inflammatory agents such as aminosalicylic acid and difuranisal.
  • FIG. 3 shows the results of efficacy confirmation tests of Examples 11 to 15 and Comparative Examples 7 to 9.
  • the solid content of the brown algae extract as the main component is appropriately set in the range of 0.05 wt% to 10.0 wt%, and the aloe extract is set in the range of 0.05 to 15.0 wt%.
  • the content is changed, and the remaining amount contains purified water and absolute ethanol.
  • the compounding amount is set to 0% or 5.0% by weight for the anti-inflammatory agent and 0% or 3.0% by weight for the soluble protein.
  • the composition of the brown algae extract-containing composition of Example 11 is as follows. (Example 11) Solid content of brown algae extract: 0.10% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 0.20% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 12 is as follows. (Example 12) Solid content of brown algae extract: 3.0% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 3.0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 13 is as follows. (Example 13) Solid content of brown algae extract: 5.0% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 14 is as follows. (Example 14) Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 10.0% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 15 is as follows. (Example 15) Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 15.0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 7 is as follows. (Comparative Example 7) Solid content of brown algae extract: 0.05% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 0.05% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 8 is as follows. (Comparative Example 8) Solid content of brown algae extract: 0.08% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 0.08% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 9 is as follows. (Comparative Example 9) Solid content of brown algae extract: 0.09 wt% Anti-inflammatory agent: 0% by weight Aloe extract: 0.10% by weight Soluble protein: 0% by weight Purified water and absolute ethanol: remaining
  • an aloe extract contains at least 1 sort (s), for example, an aloe vera mesophyll powder, Kidachi aloe mesophyll powder, a cape aloe mesophyll powder, an aloe vera leaf extract, a Kidachi aloe leaf extract, and a cape aloe leaf extract.
  • s for example, an aloe vera mesophyll powder, Kidachi aloe mesophyll powder, a cape aloe mesophyll powder, an aloe vera leaf extract, a Kidachi aloe leaf extract, and a cape aloe leaf extract.
  • a combination of a plurality of aloe extract components in the range of 0.20 to 10.00% by weight.
  • FIG. 4 shows the results of the efficacy confirmation test of Examples 16 to 20 and Comparative Examples 10 to 12.
  • the solid content of the brown alga extract as the main component is appropriately set in the range of 0.05% to 10.0% by weight, and the soluble protein is contained in the range of 0.05 to 10.0% by weight.
  • the amount is varied and the remaining amount contains purified water and absolute ethanol.
  • the compounding amount is set to 0% by weight or 5.0% by weight for the anti-inflammatory agent and 0% by weight or 5.0% by weight for the aloe extract.
  • the composition of the brown algae extract-containing composition of Example 16 is as follows. (Example 16) Solid content of brown algae extract: 0.10% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 0.10% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 17 is as follows. (Example 17) Solid content of brown algae extract: 3.0% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 0% by weight Soluble protein: 3.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 18 is as follows. (Example 18) Solid content of brown algae extract: 5.0% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 5.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 19 is as follows. (Example 19) Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 0% by weight Soluble protein: 6.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Example 20 is as follows. (Example 20) Solid content of brown algae extract: 10.0% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 10.0% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 10 is as follows. (Comparative Example 10) Solid content of brown algae extract: 0.05% by weight Anti-inflammatory agent: 0% by weight Aloe extract: 0% by weight Soluble protein: 0.05% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 11 is as follows. (Comparative Example 11) Solid content of brown algae extract: 0.08% by weight Anti-inflammatory agent: 5.0% by weight Aloe extract: 5.0% by weight Soluble protein: 0.08% by weight Purified water and absolute ethanol: remaining
  • the composition of the brown algae extract-containing composition of Comparative Example 12 is as follows. (Comparative Example 12) Solid content of brown algae extract: 0.09 wt% Anti-inflammatory agent: 0% by weight Aloe extract: 0% by weight Soluble protein: 0.09% by weight Purified water and absolute ethanol: remaining
  • the soluble protein contained in the range of 0.10 to 10.00% by weight was effective in improving manic diseases.
  • the soluble protein is preferably set in the range of 0.10 to 5.0% by weight.
  • a soluble protein is a hydrolysis silk, for example, it is not the meaning which excludes soluble proteins other than the illustrated hydrolysis silk.
  • the brown algae extract-containing composition according to the present embodiment can be used as a treatment / prevention solution for hemorrhoid diseases by applying it to the anus.
  • an efficacy test was performed on 50 subjects. Although the number of subjects is as small as 50, since the hemorrhoid disease is a disease that develops in the anus, there is a current situation that subjects are difficult to gather due to the nature of the disease.
  • FIG. 5 shows a state outside the anus of the subject.
  • 1 is an anus
  • 2 is wart
  • 3 is cut
  • 4 is itchy
  • 5 is a symptom of swelling.
  • FIG. 5 when classified according to the symptoms of the anal region, there are 3 injuries, 18 in one wart, 5 in 2 warts, 4 in warts, 4 in many warts, cuts / swells / itchiness There were 29 people.
  • the test subject who has a symptom of cutting, swelling, and itch partially overlaps with a test subject having other symptoms.
  • FIG. 6 shows the state of the anus of the subject before using the brown algae extract-containing composition as a treatment / prevention solution for hemorrhoid diseases.
  • 11 were less than 1 year ago, 18 were less than 1-5 years ago, 11 were less than 6-19 years ago, and 10 were more than 20 years ago. It was a person.
  • the test subject who has a symptom of cutting, swelling, and itch partially overlaps with a test subject having other symptoms.
  • FIG. 7 shows the usage frequency of the subject. As shown in FIG. 7, when classified according to frequency of use, 38 people once a day, 10 people twice a day, 0 people more than 3 times a day, 1 person every 2 to 3 days, 4 One person per day or more.
  • FIG. 8 shows the usage period of the subject. As shown in FIG. 8, when classified according to the period of use, 1 to 3 days are 0 people, 4 to 10 days are 15 people, 11 to 20 days are 27 people, 21 to 30 days are 4 people, 30 There were four people over the day.
  • FIG. 9 shows the state of the anus of the subject after using the brown algae extract-containing composition as a treatment / prevention solution for hemorrhoid diseases.
  • the brown algae extract-containing acupuncture prevention liquid As shown in FIG. 9, when classified according to the state of the anus after using the brown algae extract-containing acupuncture prevention liquid, there were 11 people who were considerably swollen, 12 people who were slightly swollen, and bleeding stopped There were 10 people, 9 people who stopped itching, 6 people who did not change much, and 2 people who did not change or deteriorated. Therefore, 42 of 50 test subjects, that is, 84%, had an improvement effect on epilepsy.
  • the brown algae extract-containing composition according to the present embodiment is mainly composed of a brown algae extract having a solid content of 0.10 to 10.00% by weight excluding moisture, and the remaining components are at least 0.10 to Contains 10.00 wt% anti-inflammatory agent, 0.20-10.00 wt% aloe extract, and 0.10-5.00 wt% soluble protein component.
  • the brown algae extract-containing composition according to the present embodiment by using it as a treatment / prevention solution for hemorrhoid disease, induction of hemorrhoid disease can be prevented and improvement is promoted even when epilepsy disease has developed. Can do.
  • the brown algae extract-containing composition according to the present embodiment contains a brown algae extract as an active ingredient as a main component, and contains at least an anti-inflammatory agent, an aloe extract, and a soluble protein component as the remaining components.
  • the above remaining components include water, ethanol and the like and are medically acceptable components, but may contain a preservative such as phenoxyethanol, for example. By containing a preservative, it is possible to prevent mold from occurring in the composition.
  • a preservative is not limited to the illustrated chemical
  • the brown alga extract containing composition which concerns on this embodiment may contain gelling agents, such as a suntan gum, for example.
  • gelling agents such as a suntan gum
  • the gelling agent is not limited to the exemplified drugs, and other gelling agents such as gellan gum may be used.
  • the present invention can be implemented in various modes different from the above-described embodiments without departing from the gist thereof.
  • the brown algae extract-containing composition and the brown algae extract-containing acupuncture preventive solution according to the present invention can prevent the induction of hemorrhoid disease or can promote improvement even if it has developed an epilepsy disease. Is expected to be widely applied as a composition that meets the standards for pharmaceuticals and quasi drugs in the Pharmaceutical Affairs Law.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

La présente invention concerne une composition contenant un extrait d'algues brunes qui contient au moins un extrait d'algues brunes en tant que principe actif et qui est capable d'empêcher l'induction d'une maladie hémorroïdaire et de favoriser l'amélioration dans le cas où une maladie hémorroïdaire se développe. La composition contenant un extrait d'algues brunes comprend, en tant que composant principal, un extrait d'algues brunes dans lequel le contenu solide, mis à part le taux d'humidité, représente 0,10 à 10,00 % en masse, et comprend, comme composants restants, de l'eau, de l'éthanol et analogues, et contient des composants médicalement acceptables. Les composants restants contiennent au moins 0,10 à 10,00 % en masse d'un agent anti-inflammatoire, 0,20 à 10,00 % en masse d'un extrait d'aloe, et 0,10 à 5,00 % en masse d'un composant protéique soluble.
PCT/JP2017/017208 2017-05-01 2017-05-01 Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes WO2018203380A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/017208 WO2018203380A1 (fr) 2017-05-01 2017-05-01 Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/017208 WO2018203380A1 (fr) 2017-05-01 2017-05-01 Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes

Publications (1)

Publication Number Publication Date
WO2018203380A1 true WO2018203380A1 (fr) 2018-11-08

Family

ID=64017048

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/017208 WO2018203380A1 (fr) 2017-05-01 2017-05-01 Composition contenant un extrait d'algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d'algues brunes

Country Status (1)

Country Link
WO (1) WO2018203380A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234259A (zh) * 1999-04-30 1999-11-10 孙富 治疗痔疮的药
JP2001233755A (ja) * 2000-02-25 2001-08-28 Yakult Honsha Co Ltd 皮膚外用剤組成物
JP2002332240A (ja) * 2001-05-09 2002-11-22 Milbon Co Ltd 育毛剤組成物
JP2011079768A (ja) * 2009-10-06 2011-04-21 National Institute Of Advanced Industrial Science & Technology メラニン生成系の生体内物質を阻害する薬剤
CN103393873A (zh) * 2013-08-15 2013-11-20 梁国才 一种治疗痔疮的外用药剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1234259A (zh) * 1999-04-30 1999-11-10 孙富 治疗痔疮的药
JP2001233755A (ja) * 2000-02-25 2001-08-28 Yakult Honsha Co Ltd 皮膚外用剤組成物
JP2002332240A (ja) * 2001-05-09 2002-11-22 Milbon Co Ltd 育毛剤組成物
JP2011079768A (ja) * 2009-10-06 2011-04-21 National Institute Of Advanced Industrial Science & Technology メラニン生成系の生体内物質を阻害する薬剤
CN103393873A (zh) * 2013-08-15 2013-11-20 梁国才 一种治疗痔疮的外用药剂

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Choose Onsen Biyosui Trial Size 20ml", 14 October 2016 (2016-10-14), Retrieved from the Internet <URL:https://web.archive.org/web/20161014161158/http://www.choose-choose.com/shopdetail/000000000002/> [retrieved on 20170523] *
"GEL and gel- Oroshiuri Senmonten Aphrodia", 23 September 2009 (2009-09-23), Retrieved from the Internet <URL:https://web.archive.org/web/20090923070745/http://www.gelandgel.jp/product/> [retrieved on 20170523] *
"Indian Hair Legendary Rinse Kekka o Motome Tsuzukeru Sento Keshohin TRYVIC.", 15 March 2016 (2016-03-15), Retrieved from the Internet <URL:https://web.archive.org/web/20160315155828/http://tryvic.emotent.jp/item/rinse> [retrieved on 20170523] *
"Komenuka Bijin Zenseibun Ichiran|Nihonsakari Komenuka Bijin NS-K Keshohin Kenko Shokuhin Nihonshu Tsuhan", 22 September 2016 (2016-09-22), Retrieved from the Internet <URL:https://web.archive.org/web/20160922061311/http://shop.nihonsakari.co.jp/shop/pages/ingre_komenuka.aspx> [retrieved on 20170523] *
"Oshiri no Ana no Yoboeki The ANL Clear Essence", 3 April 2016 (2016-04-03), Retrieved from the Internet <URL:https://web.archive.org/web/20160403181736/http://rams-marks.jp/category/item-detail/apl-anl> [retrieved on 20170517] *
"rams-marks shopping cart", 28 November 2015 (2015-11-28), Retrieved from the Internet <URL:https://web.archive.org/web/20151128140524/http://rams-marks.jp:80/category/126> [retrieved on 20170517] *

Similar Documents

Publication Publication Date Title
Shahzad et al. Effectiveness of Aloe Vera gel compared with 1% silver sulphadiazine cream as burn wound dressing in second degree burns
WO1993011780A1 (fr) Melange therapeutique pour la peau, contenant un extrait d&#39;aloes vera traite a froid dont la seve jaune et l&#39;aloine ont ete enlevees
JP2011522831A (ja) ナノシルバーを含むニキビ治療用組成物及びその使用
CN109620879A (zh) 一种清湿修复膏及其制备方法
WO2018203380A1 (fr) Composition contenant un extrait d&#39;algues brunes, et liquide de traitement prophylactique et thérapeutique des hémorroïdes contenant un extrait d&#39;algues brunes
EP2149378B1 (fr) Formulations topiques pour le traitement symptomatiques de troubles musculo-squelettiques
WO2012059874A1 (fr) Composition pour bain de bouche destinée au traitement de la mucosite orale, son procédé et ses méthodes
KR102474935B1 (ko) 파에오놀 및 판테놀 또는 이들의 약학적으로 허용가능한 염을 유효성분으로 포함하는 약학적 조성물
US8475852B2 (en) Topical therapeautic composition and palliative treatment method
JP6886570B2 (ja) 褐藻エキス含有痔治療予防液
JP2021080297A (ja) 褐藻エキス含有組成物
US10071052B2 (en) Method for the prevention and treatment of acne
CN109432005A (zh) 一种含有海洋寡糖的过敏性皮炎喷剂
CN111728903B (zh) 包含柠檬香蜂草提取物作为有效成分的注射剂及化妆料组合物
CN109276594A (zh) 一种用于治疗蛇串疮的中药组合物及其制备方法
EP3129031B1 (fr) Composition utilisée pour le traitement des troubles gastriques
US8741360B2 (en) Topical therapeutic composition and palliative treatment method
Tangjitjareonkun et al. Application of Aloe vera on wound healing
US20230032283A1 (en) Topical Compositions For Treating Skin Ailments
US20240148842A1 (en) Proteolytic enzyme mixture for treating psoriasis
Horaginamath et al. Effect of Talisadi Taila in the management of Sadhyo Vrana-A Case Study
CN117797086A (zh) 一种抗炎祛痘药用凝胶及其制备方法
WO2019162959A1 (fr) Formulation médicinale pour le traitement de la toux, d&#39;une angine et d&#39;une infection de la gorge
WO2020201847A1 (fr) Composition à base d&#39;herbes pour le traitement de brûlures
CN109966377A (zh) 一种外用药

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17908324

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17908324

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP